News | 18 January 2023
Cipla launches Cippoint
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
APAC to see a reduction in imported surgical robotics
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Swiftmelt 1515-I meets performance requirements and secures skin attachment
The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Subscribe To Our Newsletter & Stay Updated
